From the source
Isomorphic Labs says it has entered a strategic research collaboration with MSD, pairing its AI drug-discovery approach with MSD's proprietary data and discovery experience.
- The company describes its drug design engine, IsoDDE, as modality-agnostic and built from foundational AI models.
- Isomorphic Labs says the system provides the predictive fidelity needed to navigate novel biological systems with unprecedented accuracy.
- The collaboration is framed around accelerating therapeutic candidates for patient populations with unmet needs.
- The announcement offers no financial terms, timelines or specific disease areas.






